ESTEVE, a leading European pharmaceutical firm based in Barcelona, Spain, has entered into a definitive agreement to acquire the Infusion Specialty Therapies (IST) Business Unit from TerSera Therapeutics LLC, marking a significant strategic expansion into the United States market. Announced on January 13, 2026, this deal underscores the growing trend of cross-Atlantic partnerships in the B2B pharmaceutical sector, particularly in specialized therapies and contract services. The acquisition includes two key on-market assets: Prialt® (ziconotide intrathecal infusion), a non-opioid treatment for severe chronic pain, and Quzyttir® (cetirizine hydrochloride injection), the first FDA-approved injectable second-generation H1 antihistamine for acute urticaria. Prialt® is already marketed in Europe by ESTEVE, making this move a consolidation of worldwide rights for the product outside China, while ESTEVE gains global rights (ex-China) for Quzyttir®.

This transaction aligns perfectly with ESTEVE's focus on highly specialized therapies addressing unmet medical needs, enhancing its portfolio in areas such as endocrinology, onco-endocrinology, and now infusion specialties. Staffan Schüberg, ESTEVE's CEO, highlighted the strategic fit, noting that the addition of Quzyttir® and US expansion for Prialt® strengthens expertise in niche markets and accelerates growth in the world's largest pharmaceutical market. The deal also brings a dedicated team of sales, marketing, and medical professionals from TerSera, bolstering ESTEVE's operational capabilities in North America. This follows ESTEVE's previous expansions, including a 2024 acquisition in rare diseases and a 2025 licensing deal for a biologic treating insulin-like growth factor 1 deficiency in children.

From a B2B perspective, this acquisition impacts pharmaceutical outsourcing, contract manufacturing, and supply chain dynamics. ESTEVE's CDMO services, which specialize in Active Pharmaceutical Ingredients (APIs) production across facilities in Spain, Mexico, China, and the USA, will benefit from integrated specialty product distribution. TerSera, focusing post-acquisition on oncology and rare diseases, views ESTEVE as the ideal partner due to their long-term collaboration on Prialt® in Europe. Edward Donovan, TerSera's CEO, emphasized the momentum built around these medicines and the sharpened strategic focus enabled by the divestiture.

The deal, advised by Perella Weinberg Partners for ESTEVE and Leerink Partners for TerSera, is expected to close in Q1 2026 pending regulatory approvals. This move exemplifies how European pharma companies are leveraging acquisitions to navigate global supply chains, regulatory landscapes, and market demands. For pharmaceutical executives and CRO/CMO leaders, it signals opportunities in infusion therapies and cross-border rights consolidation. ESTEVE's commitment to transparency, accountability, and specialized solutions positions it well amid evolving regulations like the EU-U.S. MRA on GMP, which could influence future inspections and compliance for such assets.

In broader industry context, this acquisition reflects ongoing consolidation in pharmaceutical outsourcing and manufacturing. As supply chains remain interconnected, companies must monitor global regulatory actions, such as FDA Warning Letters, which can impact European operations. ESTEVE's expansion enhances its competitive edge in **Pharmaceutical Outsourcing**, **Contract Services**, and **Pharmaceutical Distribution and Logistics**. The infusion unit's focus on non-opioid pain management and antihistamine injections addresses key areas in **Pharmaceutical Formulations** and **Pharmaceutical Active Ingredients**, potentially influencing procurement strategies for R&D heads and manufacturing managers.

Regulatory teams will note the implications for compliance across jurisdictions, with ESTEVE's established European presence ensuring seamless integration. Technology vendors in laboratory automation and cleanroom solutions may find partnership opportunities as ESTEVE scales US operations. Overall, this deal reinforces Europe's role as a gateway for global pharma success, driving innovation in **Contract Manufacturing** and **Pharmaceutical Supply Chain Solutions**. Stakeholders should watch for post-closure updates on integration and market performance, which could set precedents for similar B2B transactions in 2026.

The strategic rationale extends to risk management in global operations, where proactive supplier oversight is paramount. ESTEVE's acquisition mitigates supply disruptions by internalizing critical assets, aligning with MHRA and EMA expectations for quality risk assessments. For procurement professionals, it highlights the value of specialized portfolios in negotiations and contracts. Manufacturing managers can anticipate advancements in infusion technology scalability through ESTEVE's API expertise.